Literature DB >> 27143654

Hypoxic tumor microenvironment: Opportunities to develop targeted therapies.

Akhil Patel1, Shilpa Sant2.   

Abstract

In recent years, there has been great progress in the understanding of tumor biology and its surrounding microenvironment. Solid tumors create regions with low oxygen levels, generally termed as hypoxic regions. These hypoxic areas offer a tremendous opportunity to develop targeted therapies. Hypoxia is not a random by-product of the cellular milieu due to uncontrolled tumor growth; rather it is a constantly evolving participant in overall tumor growth and fate. This article reviews current trends and recent advances in drug therapies and delivery systems targeting hypoxia in the tumor microenvironment. In the first part, we give an account of important physicochemical changes and signaling pathways activated in the hypoxic microenvironment. This is then followed by various treatment strategies including hypoxia-sensitive signaling pathways and approaches to develop hypoxia-targeted drug delivery systems. Published by Elsevier Inc.

Entities:  

Keywords:  HIF-1; Hypoxia; Physicochemical change; Solid tumor microenvironment; Targeted therapy; pH targeted

Mesh:

Substances:

Year:  2016        PMID: 27143654      PMCID: PMC4947437          DOI: 10.1016/j.biotechadv.2016.04.005

Source DB:  PubMed          Journal:  Biotechnol Adv        ISSN: 0734-9750            Impact factor:   14.227


  109 in total

1.  IFN-gamma and pro-inflammatory cytokine production by antigen-presenting cells is dictated by intracellular thiol redox status regulated by oxygen tension.

Authors:  Yukie Murata; Toshiaki Ohteki; Shigeo Koyasu; Junji Hamuro
Journal:  Eur J Immunol       Date:  2002-10       Impact factor: 5.532

2.  A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation).

Authors:  Subhra K Biswas; Lisa Gangi; Saki Paul; Tiziana Schioppa; Alessandra Saccani; Marina Sironi; Barbara Bottazzi; Andrea Doni; Bronte Vincenzo; Fabio Pasqualini; Luca Vago; Manuela Nebuloni; Alberto Mantovani; Antonio Sica
Journal:  Blood       Date:  2005-11-03       Impact factor: 22.113

Review 3.  Multi-modal strategies for overcoming tumor drug resistance: hypoxia, the Warburg effect, stem cells, and multifunctional nanotechnology.

Authors:  Lara Milane; Shanthi Ganesh; Shruti Shah; Zhen-Feng Duan; Mansoor Amiji
Journal:  J Control Release       Date:  2011-04-08       Impact factor: 9.776

Review 4.  Hypoxia in cancer: significance and impact on clinical outcome.

Authors:  Peter Vaupel; Arnulf Mayer
Journal:  Cancer Metastasis Rev       Date:  2007-06       Impact factor: 9.264

5.  Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer.

Authors:  D Rischin; L Peters; R Hicks; P Hughes; R Fisher; R Hart; M Sexton; I D'Costa; R von Roemeling
Journal:  J Clin Oncol       Date:  2001-01-15       Impact factor: 44.544

6.  Targeting of tumor-associated macrophages made possible by PEG-sheddable, mannose-modified nanoparticles.

Authors:  Saijie Zhu; Mengmeng Niu; Hannah O'Mary; Zhengrong Cui
Journal:  Mol Pharm       Date:  2013-08-06       Impact factor: 4.939

Review 7.  Hypoxia-activated prodrugs in cancer therapy: progress to the clinic.

Authors:  William A Denny
Journal:  Future Oncol       Date:  2010-03       Impact factor: 3.404

8.  Hypoxia-inducible regulation of a prodrug-activating enzyme for tumor-specific gene therapy.

Authors:  Toru Shibata; Amato J Giaccia; J Martin Brown
Journal:  Neoplasia       Date:  2002 Jan-Feb       Impact factor: 5.715

9.  Lysozyme as a pH-responsive valve for the controlled release of guest molecules from mesoporous silica.

Authors:  Mengjun Xue; Gerhard H Findenegg
Journal:  Langmuir       Date:  2012-12-05       Impact factor: 3.882

10.  Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs.

Authors:  Jian-Xin Duan; Hailong Jiao; Jacob Kaizerman; Timothy Stanton; James W Evans; Leslie Lan; Gustavo Lorente; Monica Banica; Don Jung; Jinwei Wang; Huaiyu Ma; Xiaoming Li; Zhijian Yang; Robert M Hoffman; W Steve Ammons; Charles P Hart; Mark Matteucci
Journal:  J Med Chem       Date:  2008-02-08       Impact factor: 7.446

View more
  46 in total

1.  Endostatin reverses immunosuppression of the tumor microenvironment in lung carcinoma.

Authors:  Xiaolin Liu; Weiwei Nie; Qi Xie; Guoling Chen; Xingyu Li; Yanrui Jia; Beibei Yin; Xun Qu; Yan Li; Jing Liang
Journal:  Oncol Lett       Date:  2017-11-21       Impact factor: 2.967

2.  Three dimensional engineered models to study hypoxia biology in breast cancer.

Authors:  Vaishali Aggarwal; Oshin Miranda; Paul A Johnston; Shilpa Sant
Journal:  Cancer Lett       Date:  2020-06-20       Impact factor: 8.679

3.  Targeting the Temporal Dynamics of Hypoxia-Induced Tumor-Secreted Factors Halts Tumor Migration.

Authors:  Manjulata Singh; Xiao-Jun Tian; Vera S Donnenberg; Alan M Watson; JingYu Zhang; Laura P Stabile; Simon C Watkins; Jianhua Xing; Shilpa Sant
Journal:  Cancer Res       Date:  2019-04-05       Impact factor: 12.701

4.  Theranostic Liposomes with Hypoxia-Activated Prodrug to Effectively Destruct Hypoxic Tumors Post-Photodynamic Therapy.

Authors:  Liangzhu Feng; Liang Cheng; Ziliang Dong; Danlei Tao; Todd E Barnhart; Weibo Cai; Meiwan Chen; Zhuang Liu
Journal:  ACS Nano       Date:  2016-12-29       Impact factor: 15.881

5.  A Hypoxia-Related lncRNA Signature Correlates with Survival and Tumor Microenvironment in Colorectal Cancer.

Authors:  Xinyang Zhong; Xuefeng He; Yaxian Wang; Zijuan Hu; Deshui Yu; Huixia Huang; Senlin Zhao; Ping Wei; Dawei Li
Journal:  J Immunol Res       Date:  2022-07-08       Impact factor: 4.493

6.  Targeted polymeric nanoparticles for drug delivery to hypoxic, triple-negative breast tumors.

Authors:  Babak Mamnoon; Jagadish Loganathan; Matthew I Confeld; Nimesha De Fonseka; Li Feng; Jamie Froberg; Yongki Choi; Daniel M Tuvin; Venkatachalem Sathish; Sanku Mallik
Journal:  ACS Appl Bio Mater       Date:  2020-12-23

7.  Ultrathin-FeOOH-Coated MnO2 Sonosensitizers with Boosted Reactive Oxygen Species Yield and Remodeled Tumor Microenvironment for Efficient Cancer Therapy.

Authors:  Qiyu Liu; Liyin Shi; Ying Liao; Xianshuo Cao; Xiaoqing Liu; Yanxia Yu; Zifan Wang; Xihong Lu; Jianwei Wang
Journal:  Adv Sci (Weinh)       Date:  2022-04-28       Impact factor: 17.521

Review 8.  Oxygen-Based Nanocarriers to Modulate Tumor Hypoxia for Ameliorated Anti-Tumor Therapy: Fabrications, Properties, and Future Directions.

Authors:  Xianqiang Li; Yue Wu; Rui Zhang; Wei Bai; Tiantian Ye; Shujun Wang
Journal:  Front Mol Biosci       Date:  2021-07-01

9.  Hypoxic TAM-derived exosomal miR-155-5p promotes RCC progression through HuR-dependent IGF1R/AKT/PI3K pathway.

Authors:  Wenyu Gu; Linjing Gong; Xu Wu; Xudong Yao
Journal:  Cell Death Discov       Date:  2021-06-15

10.  Hypoxia-Responsive, Polymeric Nanocarriers for Targeted Drug Delivery to Estrogen Receptor-Positive Breast Cancer Cell Spheroids.

Authors:  Babak Mamnoon; Li Feng; Jamie Froberg; Yongki Choi; Venkatachalem Sathish; Sanku Mallik
Journal:  Mol Pharm       Date:  2020-09-29       Impact factor: 5.364

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.